Orlistat (92) is an FDA-approved anti-obesity drug that targets the FASN thioesterase activity, although it also irreversibly inhibits pancreatic and gastric lipases (93). This evidence concerns the gene FASN and obesity due to melanocortin 4 receptor deficiency.